Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AAV8-TBG-GFP-mESR1-shRNAmir is a hepatocyte-specific gene knockdown vector delivered via an adeno-associated virus serotype 8 (AAV8) capsid. It utilizes the thyroxine-binding globulin (TBG) promoter to drive the expression of a microRNA-adapted short hairpin RNA (shRNAmir) targeting the mouse Estrogen Receptor 1 (Esr1) gene, which encodes Estrogen Receptor Alpha (ERα). The construct also includes a Green Fluorescent Protein (GFP) reporter for visualization of transduction. This tool is primarily used in preclinical research to investigate the role of hepatic ERα signaling in metabolic disorders such as Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD). Studies have shown that hepatocyte-specific knockdown of ERα using this vector exacerbates high-fat diet-induced steatosis, liver injury, and glucose intolerance in female mice.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on AAV8-TBG-GFP-mESR1-shRNAmir.